Displaying drugs 15001 - 15025 of 15165 in total
DG051
DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4...
Investigational
Matched Description: … attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and …
ATX-201
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic
keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their...
Investigational
Matched Description: … The Company determined that the program was not meeting their expected primary and exploratory objectives …
(1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide
(1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide is a solid. This compound belongs to the oxepanes. These are compounds containing an oxepane ring, which is an a seven-member saturated aliphatic heterocycle with one oxygen and six carbon atoms. This drug targets the protein beta-glucosidase A.
Experimental
Matched Description: … containing an oxepane ring, which is an a seven-member saturated aliphatic heterocycle with one oxygen and …
4SC-203
4SC-203 has been used in trials studying the treatment of Acute Myeloid Leukemia.
Investigational
Sorbinil
Experimental
Investigational
NV-18
NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma...
Investigational
Matched Description: … almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and …
Sirna-027
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. …
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal
C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal muscle breakdown. C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. Calpain is...
Investigational
Matched Description: … C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. …
BW-A 58C
BW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by a 54 kDa CYP2C9 form of cytochrome P450, P450hB20-27.
Experimental
Matched Description: … which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and …
Deracoxib
Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to treat osteoarthritis in dogs. It is sold in tablets, which have added beefy flavour to increase palatability. Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation associated with...
Vet approved
Matched Description: … Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation …
XMT-1001
XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity. It is a water-soluble macromolecular conjugate of camptothecin (CPT). In this novel CPT pro-drug, CPT is conjugated with a 70 kDa biodegradable hydrophilic polyacetal, poly (1-hydroxymethylene hydroxylmethylformal). XMT-1001 has demonstrated an improved therapeutic...
Investigational
Matched Description: … XMT-1001 has demonstrated an improved therapeutic window as compared with CPT and irinotecan in human …
Nelotanserin
Nelotanserin has been used in trials studying the treatment of Lewy Body Dementia, Visual Hallucinations, Dementia With Lewy Bodies, and REM Sleep Behavior Disorder. It is a highly selective antagonist at the 5-HT2A serotonin receptor. It increases non-REM sleep, the most restorative phase of the sleep cycle, without sacrificing REM...
Investigational
Matched Description: … trials studying the treatment of Lewy Body Dementia, Visual Hallucinations, Dementia With Lewy Bodies, and …
CRx-139
CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the...
Investigational
Matched Description: … The synergistic combination containing low doses of the glucocorticoid steroid prednisolone and the antidepressant …
Hexamethonium
A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by...
Experimental
Matched Description: … It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. …
Urapidil
Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia.
Investigational
Patidegib
Patidegib has been investigated for the treatment of Conventional Chondrosarcoma.
Investigational
PCO-371
PCO-371 is under investigation in clinical trial NCT02475616 (A Single Ascending Dose Study of PCO371 in Healthy Volunteers).
Investigational
CTS-21166
CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent...
Investigational
Matched Description: … currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability, and …
Ivarmacitinib
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Matched Description: … graft-versus-host disease,[A245653,L40599] vitiligo,[L40609] ulcerative colitis,[L40614] alopecia areata,[L40624] and …
AMG-131
AMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin. T131...
Investigational
Matched Description: … is not structurally related to the thiazolidinedione class of PPARg agonists, which includes Actos and …
Displaying drugs 15001 - 15025 of 15165 in total